Palisade Bio (PALI) Competitors $0.60 +0.02 (+2.75%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$0.60 +0.00 (+0.17%) As of 09/12/2025 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PALI vs. ALLR, NAII, SNYR, NEUP, PASG, NNVC, SONN, RLYB, CTXR, and TAOXShould you be buying Palisade Bio stock or one of its competitors? The main competitors of Palisade Bio include Allarity Therapeutics (ALLR), Natural Alternatives International (NAII), Synergy CHC (SNYR), Neuphoria Therapeutics (NEUP), Passage Bio (PASG), NanoViricides (NNVC), Sonnet BioTherapeutics (SONN), Rallybio (RLYB), Citius Pharmaceuticals (CTXR), and Synaptogenix (TAOX). These companies are all part of the "pharmaceutical products" industry. Palisade Bio vs. Its Competitors Allarity Therapeutics Natural Alternatives International Synergy CHC Neuphoria Therapeutics Passage Bio NanoViricides Sonnet BioTherapeutics Rallybio Citius Pharmaceuticals Synaptogenix Palisade Bio (NASDAQ:PALI) and Allarity Therapeutics (NASDAQ:ALLR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations, valuation and media sentiment. Do analysts recommend PALI or ALLR? Palisade Bio presently has a consensus target price of $12.00, indicating a potential upside of 1,906.69%. Allarity Therapeutics has a consensus target price of $9.00, indicating a potential upside of 442.17%. Given Palisade Bio's higher probable upside, equities analysts plainly believe Palisade Bio is more favorable than Allarity Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Palisade Bio 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Allarity Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals believe in PALI or ALLR? 11.8% of Palisade Bio shares are owned by institutional investors. Comparatively, 11.5% of Allarity Therapeutics shares are owned by institutional investors. 0.7% of Palisade Bio shares are owned by company insiders. Comparatively, 0.1% of Allarity Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is PALI or ALLR more profitable? Allarity Therapeutics' return on equity of -173.31% beat Palisade Bio's return on equity.Company Net Margins Return on Equity Return on Assets Palisade BioN/A -214.94% -135.09% Allarity Therapeutics N/A -173.31%-102.57% Which has more risk & volatility, PALI or ALLR? Palisade Bio has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500. Comparatively, Allarity Therapeutics has a beta of 0.16, indicating that its stock price is 84% less volatile than the S&P 500. Does the media favor PALI or ALLR? In the previous week, Palisade Bio had 4 more articles in the media than Allarity Therapeutics. MarketBeat recorded 7 mentions for Palisade Bio and 3 mentions for Allarity Therapeutics. Allarity Therapeutics' average media sentiment score of 0.62 beat Palisade Bio's score of 0.44 indicating that Allarity Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palisade Bio 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Allarity Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings and valuation, PALI or ALLR? Palisade Bio has higher revenue and earnings than Allarity Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPalisade Bio$250K21.82-$14.44M-$4.06-0.15Allarity TherapeuticsN/AN/A-$24.51MN/AN/A SummaryPalisade Bio beats Allarity Therapeutics on 8 of the 11 factors compared between the two stocks. Get Palisade Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for PALI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PALI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PALI vs. The Competition Export to ExcelMetricPalisade BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.31M$3.20B$5.87B$10.13BDividend YieldN/A2.30%5.68%4.60%P/E Ratio-0.1521.1774.5225.93Price / Sales21.82435.97518.91181.69Price / CashN/A46.6837.5660.44Price / Book0.229.6112.166.29Net Income-$14.44M-$53.29M$3.28B$270.77M7 Day Performance-4.55%0.12%0.78%3.84%1 Month Performance-26.25%5.60%4.87%4.85%1 Year Performance-84.22%10.47%60.72%26.00% Palisade Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PALIPalisade Bio3.0918 of 5 stars$0.60+2.7%$12.00+1,906.7%-84.0%$5.31M$250K-0.1510Short Interest ↓Gap DownALLRAllarity Therapeutics1.9647 of 5 stars$1.63+5.7%$9.00+452.8%-42.4%$23.76MN/A0.0010Short Interest ↑NAIINatural Alternatives International1.6588 of 5 stars$3.80+6.1%N/A-44.0%$23.48M$113.80M-2.73290Short Interest ↓SNYRSynergy CHC4.0723 of 5 stars$2.39-1.2%$10.00+318.4%+980.0%$22.56M$34.83M6.2940News CoverageNEUPNeuphoria Therapeutics2.5845 of 5 stars$11.96+5.6%$21.00+75.6%N/A$22.49M$10K0.00N/ANews CoverageAnalyst ForecastPASGPassage Bio3.9345 of 5 stars$7.07-0.9%$91.75+1,198.7%-53.1%$22.47MN/A-0.39130NNVCNanoViricides0.1551 of 5 stars$1.39flatN/A-13.7%$22.34MN/A-1.9320Short Interest ↑SONNSonnet BioTherapeutics2.8843 of 5 stars$3.19-2.0%$20.00+527.9%-7.9%$22.01M$20K0.0010Positive NewsGap UpRLYBRallybio3.3989 of 5 stars$0.53-2.2%$5.00+852.4%-45.4%$21.98M$640K-0.5640Positive NewsShort Interest ↓CTXRCitius Pharmaceuticals2.3765 of 5 stars$1.28-4.1%$53.00+4,056.9%-90.6%$21.69MN/A0.0020Analyst UpgradeShort Interest ↑TAOXSynaptogenix0.1175 of 5 stars$6.21+6.7%N/AN/A$21.67MN/A-0.314Positive News Related Companies and Tools Related Companies ALLR Alternatives NAII Alternatives SNYR Alternatives NEUP Alternatives PASG Alternatives NNVC Alternatives SONN Alternatives RLYB Alternatives CTXR Alternatives TAOX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PALI) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palisade Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Palisade Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PALI Stock Alerts